

# New Venturetec

## NET ASSET VALUE - September 30, 2018

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	<u>500'000</u>	Price: CHF 33.00 (ex.rate 1.47)	<u>USD 11'250'000</u>
	<b>5,000,000</b>		<b>USD 118'500'000</b>

<b>Total paid in capital</b>	<b>USD</b>	<b>118'500'000.00</b>
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	75'269'925.93
Realized loss* (since inception to date)	USD	109'585'211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	24'430'907.46
Unrealized loss	USD	<u>0.00</u>
<b>Total appreciation</b>	<b>USD</b>	<b>24'430'907.46</b>

### NAV

Cost of investments	USD	28'475'733.64
Appreciation of investments	USD	<u>24'430'907.46</u>
Estimated value of investments	USD	<b>52'906'641.10</b>
Convertible Notes	USD	-13'599'404.39
Loan	USD	-7'829'701.38
Bank Loan	USD	0.00
Accrued expenses	USD	-77'280.00
Accounts receivables	USD	0.00
Cash at bank	USD	<u>956'755.93</u>
<b>Estimated value</b>	<b>USD</b>	<b>32'357'011.25</b>
<b>NAV per share USD</b>		<b>6.47</b>
<b>NAV per share CHF</b>		<b>6.35</b>

Exchange rate USD/CHF	0.9816
<b>Closing Market Price September 30, 2018</b>	<b>CHF 5.10</b>

## New Venturetec

### NAV - September 30, 2018

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23'780'932.93	83.5	4'103'301 Common Shares	5.80	11.10	21'765'708.17	45'546'641.10	84.5
2. Myriad Genetics	4'694'800.71	16.5	160'000 Shares	29.34	46.00	2'665'199.29	7'360'000.00	13.7
<b>TOTAL</b>	<b>28'475'733.64</b>	<b>100.0</b>				<b>24'430'907.46</b>	<b>52'906'641.10</b>	<b>98.2</b>